GCTK

Glucotrack is not an operating business you can value on fundamentals — it is a preclinical medical-device R&D program with no approved product and no material revenue. Management states plainly that its first product's CE Mark was withdrawn in 2023 with all commercialization halted, and its only asset now, the Glucotrack CBGM implantable monitor, is 'currently under preclinical development,' not approved anywhere. The lone revenue figure in the data ($208K) is from FY2019; there has been no meaningful top line since, so the reported P/S of 3.0 and the $31.22 'diluted EPS' (yielding a nonsense 0.0 P/E) are artifacts of stale data and share-count mechanics, not signal. FY2025 was a $19.4M net loss on a -9,321% net margin, with R&D of $9.81M the dominant spend.

The balance sheet is the whole story and it is a countdown clock. The company held $7.38M cash at year-end 2025 against operating cash outflow of $15.2M — roughly five months of runway at the current burn — and management explicitly warns it 'will seek additional capital through... private and public equity offerings and debt financings' and expects losses to 'likely increase' as it develops CBGM. That means near-certain, imminent, highly dilutive financing. The equity base is razor-thin: $2.83M stockholders' equity against a $152M accumulated deficit, with current liabilities up 274% YoY.